In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients
Anna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad · 2025
Read In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients by Anna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12660821.txt.
Description
Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates vary widely between subgroups, with an average overall survival of 70%. Recurrent medulloblastoma is highly aggressive, treatment-resistant, and usually fatal. In addition, current treatments are highly toxic to the developing brain and surviving patients suffer from lifelong side effects. Therefore, novel therapeutic options are urgently needed.
Catalog record
| CREATOR | Anna M. Jermakowicz, Luz Ruiz, Jonathan Chu, Nitish Jangde, Robert K. Suter, Nina S. Kadan-Lottick, Derek Hanson, Nagi G. Ayad |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |